Swisse

Main information

  • Trade name:
  • Swisse Ultiboost Magnesium Orotate
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Swisse Ultiboost Magnesium Orotate
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 220775
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

220775

Swisse Ultiboost Magnesium Orotate

ARTG entry for

Medicine Listed

Sponsor

Swisse Wellness Pty Ltd

Postal Address

111 Cambridge Street,Collingwood, VIC, 3066

Australia

ARTG Start Date

6/03/2014

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Products

1. Swisse Ultiboost Magnesium Orotate

Product Type

Single Medicine Product

Effective date

18/08/2016

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Specific Indications

Magnesium helps the body to metabolise carbohydrates and fats

Magnesium is involved in the production of cellular energy/may assist with cellular energy production

Magnesium helps support healthy muscle function

Magnesium supports muscle relaxation by competitively binding to receptor sites normally reserved for calcium, which is the mineral that causes muscles

to contract. A depletion of Magnesium, due to low dietary intake, may lead to muscle cramps and spasms/Magnesium supplementation may provide

support for muscle cramps and spasms when dietary intake of magnesium is low

Calcium and magnesium work together to cause the contraction and relaxation of muscles.

Magnesium supplementation may provide support for muscle cramps and spasms when dietary intake of magnesium is low/ Increased calcium and a

depletion of magnesium, due to low dietary intake, may lead to muscle cramps.

Magnesium levels may be lower in women with PMS

Magnesium helps support general health and wellbeing

Magnesium helps support a healthy nervous system/nervous system support. Adequate levels of magnesium are important during times of stress.

Magnesium plays an important role in supporting adrenal health, the adrenal glands have a key role in the body's response to stress. Provides adrenal

support during times of stress.

Factors such as diet and excess alcohol intake may reduce magnesium levels

Adequate levels of magnesium contribute to a healthy cardiovascular system/help to support/maintain heart health/assists a health cardiovascular

system Magnesium plays a structural role in bones, it is also required for the transport of calcium across cell membranes.

The magnesium orotate compound contains two components-magnesium and orotic acid. Orotic acid acts as a transporter, carrying magnesium into the

cells.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Active Ingredients

Magnesium orotate dihydrate

820.31 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 26.11.2017 at 02:05:11 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

8-9-2009

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

On 3 september 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds).

Danish Medicines Agency

4-5-2009

Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

Danish Medicines Agency

7-8-2018

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (AstraZeneca AB)

Duaklir Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5419 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

7-8-2018

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (AstraZeneca AB)

Brimica Genuair (Active substance: aclidinium bromide / formoterol fumarate dihydrate) - Centralised - Yearly update - Commission Decision (2018)5420 of Tue, 07 Aug 2018

Europe -DG Health and Food Safety

19-6-2018

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Active substance: oxalic acid dihydrate) - Centralised - Authorisation - Commission Decision (2018)3892 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4667

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety

5-2-2018

Oxybee (Dany Bienenwohl GmbH)

Oxybee (Dany Bienenwohl GmbH)

Oxybee (Active substance: oxalic acid dihydrate) - New authorisation - Commission Decision (2018)684 of Mon, 05 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4296

Europe -DG Health and Food Safety